Lexicon Pharmaceuticals vs Sutro Biopharma
Sutro Biopharma is the larger business, with $102m of revenue in fiscal 2025 against $49.8m for Lexicon Pharmaceuticals (2.1 times as much). Sutro Biopharma grew faster (65.2% against 60.2%). Lexicon Pharmaceuticals kept more of each dollar of sales as profit: a net margin of -101.1% against -186.5%.
| Latest fiscal year | Lexicon PharmaceuticalsLXRX, 2025 | Sutro BiopharmaSTRO, 2025 |
|---|---|---|
| Revenue | $49.8m | $102m |
| Revenue growth | 60.2% | 65.2% |
| Net income | −$50.3m | −$191m |
| Operating margin | -98.2% | — |
| Net margin | -101.1% | -186.5% |
| Return on equity | -39.7% | — |
| Free cash flow | −$67.9m | −$177m |
| Cash | $34.3m | $58.1m |
| Total debt | $54.0m | $0 |
| Debt to equity | 50.2% | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | — | 137 |
| Market value | $643m | $151m |
| Price vs our value range | — | — |
| Moat score | 26 (Weak) | 14 (Weak) |
| Insider trades, 12 months | 8 buys, 0 sales | 0 buys, 0 sales |